100 related articles for article (PubMed ID: 9724059)
1. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat.
Yamamoto M; Murakami T; Nishikawa M; Tsuda E; Mochizuki S; Higashio K; Akatsu T; Motoyoshi K; Nagata N
Endocrinology; 1998 Sep; 139(9):4012-5. PubMed ID: 9724059
[TBL] [Abstract][Full Text] [Related]
2. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
Yasuda H; Shima N; Nakagawa N; Mochizuki SI; Yano K; Fujise N; Sato Y; Goto M; Yamaguchi K; Kuriyama M; Kanno T; Murakami A; Tsuda E; Morinaga T; Higashio K
Endocrinology; 1998 Mar; 139(3):1329-37. PubMed ID: 9492069
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.
Murakami T; Yamamoto M; Ono K; Nishikawa M; Nagata N; Motoyoshi K; Akatsu T
Biochem Biophys Res Commun; 1998 Nov; 252(3):747-52. PubMed ID: 9837778
[TBL] [Abstract][Full Text] [Related]
4. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH.
Ueno Y; Shinki T; Nagai Y; Murayama H; Fujii K; Suda T
J Cell Biochem; 2003 Oct; 90(2):267-77. PubMed ID: 14505343
[TBL] [Abstract][Full Text] [Related]
5. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
[TBL] [Abstract][Full Text] [Related]
6. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells.
Kanzawa M; Sugimoto T; Kanatani M; Chihara K
Eur J Endocrinol; 2000 Jun; 142(6):661-4. PubMed ID: 10822231
[TBL] [Abstract][Full Text] [Related]
7. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
Yano K; Tsuda E; Washida N; Kobayashi F; Goto M; Harada A; Ikeda K; Higashio K; Yamada Y
J Bone Miner Res; 1999 Apr; 14(4):518-27. PubMed ID: 10234572
[TBL] [Abstract][Full Text] [Related]
8. [Osteoclastogenesis inhibitory factor (OCIF)/OPG].
Tsuda E; Higashio K
Nihon Rinsho; 1998 Jun; 56(6):1435-9. PubMed ID: 9648461
[TBL] [Abstract][Full Text] [Related]
9. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy.
Akatsu T; Murakami T; Ono K; Nishikawa M; Tsuda E; Mochizuki SI; Fujise N; Higashio K; Motoyoshi K; Yamamoto M; Nagata N
Bone; 1998 Dec; 23(6):495-8. PubMed ID: 9855457
[TBL] [Abstract][Full Text] [Related]
10. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.
Kazama JJ; Shigematsu T; Yano K; Tsuda E; Miura M; Iwasaki Y; Kawaguchi Y; Gejyo F; Kurokawa K; Fukagawa M
Am J Kidney Dis; 2002 Mar; 39(3):525-32. PubMed ID: 11877571
[TBL] [Abstract][Full Text] [Related]
11. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.
Morony S; Capparelli C; Lee R; Shimamoto G; Boone T; Lacey DL; Dunstan CR
J Bone Miner Res; 1999 Sep; 14(9):1478-85. PubMed ID: 10469275
[TBL] [Abstract][Full Text] [Related]
12. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
Ma YL; Cain RL; Halladay DL; Yang X; Zeng Q; Miles RR; Chandrasekhar S; Martin TJ; Onyia JE
Endocrinology; 2001 Sep; 142(9):4047-54. PubMed ID: 11517184
[TBL] [Abstract][Full Text] [Related]
13. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.
Hakeda Y; Kobayashi Y; Yamaguchi K; Yasuda H; Tsuda E; Higashio K; Miyata T; Kumegawa M
Biochem Biophys Res Commun; 1998 Oct; 251(3):796-801. PubMed ID: 9790989
[TBL] [Abstract][Full Text] [Related]
14. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
[TBL] [Abstract][Full Text] [Related]
15. Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy.
Yano K; Shibata O; Mizuno A; Kobayashi F; Higashio K; Morinaga T; Tsuda E
Biochem Biophys Res Commun; 2001 Oct; 288(1):217-24. PubMed ID: 11594776
[TBL] [Abstract][Full Text] [Related]
16. Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers.
Uemura H; Yasui T; Kiyokawa M; Kuwahara A; Ikawa H; Matsuzaki T; Maegawa M; Furumoto H; Irahara M
J Endocrinol; 2002 Aug; 174(2):353-9. PubMed ID: 12176675
[TBL] [Abstract][Full Text] [Related]
17. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
Mochizuki S; Kiyokawa A; Nagayama Y
Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
[TBL] [Abstract][Full Text] [Related]
18. Basic fibroblast growth factor inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D(3) through suppressing the production of osteoclast differentiation factor.
Nakagawa N; Yasuda H; Yano K; Mochizuki Si; Kobayashi N; Fujimoto H; Yamaguchi K; Shima N; Morinaga T; Higashio K
Biochem Biophys Res Commun; 1999 Nov; 265(1):45-50. PubMed ID: 10548488
[TBL] [Abstract][Full Text] [Related]
19. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
20. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.
Akatsu T; Murakami T; Nishikawa M; Ono K; Shinomiya N; Tsuda E; Mochizuki S; Yamaguchi K; Kinosaki M; Higashio K; Yamamoto M; Motoyoshi K; Nagata N
Biochem Biophys Res Commun; 1998 Sep; 250(2):229-34. PubMed ID: 9753612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
